---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095451"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:54.939375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical Q2 net loss narrows to $7.6M; Phase 2b wet AMD trial on track for late Q3 data

## Summary
- Net loss of $7.6M ($0.10/sh) vs $9.1M ($0.15/sh) in Q2 2023; license revenue $90,000.
- Phase 2b ODYSSEY topline data for wet AMD expected late Q3 2024; no drug-related SAEs observed.
- Cash and investments total $29.4M; company expects operations funded into Q3 2025.
- Arctic Vision reports positive Phase 3 ARCATUS results; NDAs accepted in Australia and Singapore.
- Tony Gibney appointed to Board; Dr. Glenn Yiu added to Scientific Advisory Board.

## SEC filing metadata
- accession: 0000950170-24-095451
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017024095451/0000950170-24-095451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017024095451/clsd-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095451
- JSON: https://secwatch.observer/filing/0000950170-24-095451.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.